Patents by Inventor David Claremon

David Claremon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Derivatives of [1,3]Oxazin-2-one useful for the treatment of metabolic diseases such as lipid disorders
    Patent number: 8598163
    Abstract: This invention relates to novel compounds of an 11 ?-HSD1 inhibitor disclosed herein, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11/3-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of Cortisol in a cell or the inhibition of the conversion of cortisone to Cortisol in a cell.
    Type: Grant
    Filed: February 3, 2010
    Date of Patent: December 3, 2013
    Assignees: Vitae Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH
    Inventors: David Claremon, Colin Tice, Suresh Singh, Yuanjie Ye, Katerina Leftheris, Linghang Zhuang
  • Renin Inhibitors
    Publication number: 20100317697
    Abstract: Disclosed are compounds having the formula (I): wherein the R1, R2, R3, X, Y, A, L, and G are defined herein. These compounds bind to aspartic proteases to inhibit their activity and are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also disclosed are methods of use of the compounds of Formula I for ameliorating or treating aspartic protease related disorders in a subject in need thereof.
    Type: Application
    Filed: June 20, 2008
    Publication date: December 16, 2010
    Inventors: John J. Baldwin, Salvacion Cacatian, David Claremon, Lawrence W. Dillard, Patrick T. Flaherty, Bahman Ghavimi-Alagha, Damiano Ghirlanda, Alexey V. Ishchenko, Lara S. Kallander, Brian Lawhorn, Qing Lu, Gerard McGeehan, Beth A. Knapp-Reid, Simon Semus, Robert D. Simpson, Suresh B. Singh, Lamont R. Terrell, Colin Tice, Tritin Tran, Zherong Xu, Jing Yuan, Wei Zhao, Yongdong Y. Zhao
  • Renin Inhibitors
    Publication number: 20100280005
    Abstract: Disclosed are compounds of Formula I, wherein the R, R1, R2, R3, X, Y, A, Q, E, and G are defined herein. These compounds bind to aspartic proteases to inhibit their activity and are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also disclosed are methods of use of the compounds of Formula I for ameliorating or treating aspartic protease related disorders in a subject in need thereof.
    Type: Application
    Filed: April 4, 2008
    Publication date: November 4, 2010
    Inventors: Jonh J. Baldwin, Salvacion Cacatian, David Claremon, Lawrence W. Dillard, Patrick T. Flaherty, Bahman Ghavimi-Alagha, John Gleason, Alexey V. Ishchenko, Brian Lawhorn, Gerard McGeehan, Jaclyn R. Patterson, Simon F. Semus, Robert D. Simpson, Suresh B. Singh, Colin Tice, Tritin Tran, Zhenrong Xu, Jing Yuan, Wei Zhao
  • RENIN INHIBITORS
    Publication number: 20100179109
    Abstract: Disclosed are compounds of Formula (I) wherein the R, R1, R2, R3, X, Y, A, Q, E, and G are defined herein. These compounds bind to aspartic proteases to inhibit their activity and are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also disclosed are methods of use of the compounds of Formula I for ameliorating or treating aspartic protease related disorders in a subject in need thereof.
    Type: Application
    Filed: April 4, 2008
    Publication date: July 15, 2010
    Inventors: Jonh J. Baldwin, Salvacion Cacatian, David Claremon, Lawrence W. Dillard, Patrick T. Flaherty, Bahman Ghavimi-Alagha, Damiano Ghirlanda, Alexey V. Ishchenko, Lara S. Kallander, Brian Lawhorn, Colin A. Leach, Qing Lu, Gerard McGeehan, Jaclyn R. Patterson, Robert D. Simpson, Suresh B. Singh, Patrick Stoy, Lamont R. Terrell, Colin Tice, Zhenrong Xu, Jing Yuan, Catherine C. K. Yuan, Jing Zhang, Wei Zhao
  • Renin Inhibitors
    Publication number: 20100130471
    Abstract: Described are compounds which bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described are methods of use of the compounds described herein in ameliorating or treating aspartic protease related disorders in a subject in need thereof.
    Type: Application
    Filed: April 4, 2008
    Publication date: May 27, 2010
    Inventors: John J. Baldwin, Salvacion Cacatian, David Claremon, Lawrence W. Dillard, Patrick T. Flaherty, Bahman Ghavimi-Alagha, Damiamo Ghirlanda, Xiaoping Hou, Alexey V. Ishebenko, Lara S. Kallander, Beth A. Knapp-Reed, Brian Lawhorn, Qing Lu, Gerard McGeehan, Simon Semus, Robert D. Simpson, Suresh B. Singh, Lamont R. Terrell, Colin Tice, Tritin Tran, Zhenrong Xu, Jing Yuan, Jing Zhang, Wei Zhao
  • N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
    Publication number: 20070149568
    Abstract: Compounds represented by Formula (I) or pharmaceutically acceptable salts thereof, are effective as NMD NR2B antagonists useful for treating conditions such as, for example, Parkinson's disease, Alzheimer's disease, migraine, epilepsy and pain.
    Type: Application
    Filed: March 10, 2004
    Publication date: June 28, 2007
    Inventors: Nigel Liverton, Christopher Claiborne, David Claremon, John McCauley
  • Isoquinoline potassium channel inhibitors
    Publication number: 20070054892
    Abstract: The present invention relates to compounds of structural formula I: I useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
    Type: Application
    Filed: September 22, 2004
    Publication date: March 8, 2007
    Inventors: Richard Isaacs, Christopher Dinsmore, B. Trotter, Nigel Liverton, Douglas Beshore, Nathan Kett, Charles McIntyre, Kausik Nanda, David Claremon
  • Isoquinolinone potassium channel inhibitors
    Publication number: 20070027177
    Abstract: The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
    Type: Application
    Filed: September 17, 2004
    Publication date: February 1, 2007
    Inventors: B. Trotter, Christopher Claiborne, Gerald Ponticello, Charles McIntyre, Nigel Liverton, David Claremon
  • Isoquinoline potassium channel inhibitors
    Publication number: 20060276450
    Abstract: The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
    Type: Application
    Filed: September 17, 2004
    Publication date: December 7, 2006
    Inventors: B. Trotter, Kausik Nanda, Nathan Kett, Christopher Dinsmore, Gerald Ponticello, David Claremon
  • Isoquinolinone potassium channel inhibitors
    Publication number: 20060270704
    Abstract: The present invention relates to compounds having the structure formula (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
    Type: Application
    Filed: September 22, 2004
    Publication date: November 30, 2006
    Inventors: Richard Isaacs, Christopher Dinsmore, Charles McIntyre, Linda Payne, David Claremon
  • 2-[(4-Benzyl)-1-piperidinyl)methyl]benzimidazole-5-ol derivatives as nr2b receptor antagonists
    Publication number: 20060160853
    Abstract: 2-[(4-Benzyl)-1-piperidinyl)-methyl]benzimidazole-5-ol derivatives are NMDA NR2B receptor antagonists useful in the treatment of pain and other NMDA mediated diseases.
    Type: Application
    Filed: November 18, 2003
    Publication date: July 20, 2006
    Inventors: John McCauley, David Claremon, Nigel Liverton